Application of 3-indoleacetic acid

By using 3-indoleacetic acid to regulate COL1A1 expression in the sclera, the problem of unknown relationship between intestinal microbiota and high myopia was solved, and the effect of slowing down the progress of myopia was achieved, and a new treatment strategy was provided.

CN118903113APending Publication Date: 2024-11-08EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202411169481.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-24
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art has not fully explored the relationship between the intestinal microbiota and high myopia, and lacks effective prevention and treatment methods, especially in regulating extracellular matrix reconstruction and scleral thinning in the eye.

Method used

3-indoleacetic acid (3-IAA) is used as a metabolite derived from the intestinal microbiota, and by regulating COL1A1 expression in the sclera as a potential therapeutic strategy to prevent or slow myopia and high myopia, including in health care products, drugs or foods An effective dose of 3-IAA was added and its effect was verified by fecal flora transplantation (FMT) experiments.

Benefits of technology

The progress of myopia was significantly slowed down in mouse models, increasing the expression of COL1A1 in the scleral, demonstrating the role of 3-IAA in maintaining scleral structural integrity, and providing a new potential strategy for the treatment of myopia and high myopia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903113A_ABST
    Figure CN118903113A_ABST
Patent Text Reader

Abstract

The invention relates to application of 3-indoleacetic acid in products for preventing or relieving myopia and high myopia. And the 3-indoleacetic acid (3-IAA) is a metabolite related to intestinal microbiota. The invention also provides an application of 3-IAA in a product for regulating expression increase of type I collagen alpha 1 chain (COL1A1) in sclera. 3-IAA is an enteric microbiota related metabolite, which is significantly altered in HM patients. Oral supplementation of 3-IAA in mice results in increased expression of COL1A1 in sclera and attenuated myopia, HM progression. The 3-IAA increases COL1A1 expression in an SP1 dependent manner, which indicates that the 3-IAA may contribute to a mechanism of maintaining sclera structural integrity. Regulating intestinal microbiota and supplementing 3-IAA are potential therapeutic strategies for preventing or slowing down myopia and HM progression.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of microbial technology, in particular to the application of 3-indoleacetic acid. Background Art

[0002] High myopia (HM) is a serious visual disorder whose core pathological feature is excessive extension of the axial length, which is usually caused by the progressive thinning of the sclera tissue. As the main supporting structure of the eyeball wall, the reduction in the thickness of the sclera weakens the mechanical stability of the eyeball and promotes the development of myopia. Studies have shown that the remodeling of the extracellular matrix (ECM), especially the degradation and rearrangement of type I collagen, is a key factor leading to scleral thinning.

[0003] In recent years, the relationship between intestinal microbiota and various diseases has gradually attracted attention. They play an important role in regulating the homeostasis of multiple systems in the body, including the role in collagen remodeling and fibrosis. Especially in the field of ophthalmology, studies have preliminarily revealed the role of intestinal microbiota in eye diseases such as uveitis and age-related macular degeneration. However, in-depth research on the relationship between intestinal microbiota and high myopia is still insufficient.

[0004] In the process of exploring the influence of gut microbiota on myopia, we discovered a metabolite called 3-indoleacetic acid (3-IAA), which is a metabolite of tryptophan produced by certain bacteria in the intestine, such as Bacteroides fragilis and Bacteroides thetaiotaomicron. 3-IAA is higher in patients with metastatic pancreatic ductal adenocarcinoma who respond to chemotherapy, and its level can be regulated by tryptophan in the diet. 3-IAA can enhance the effect of cancer chemotherapy, and its mechanism involves myeloperoxidase-mediated 3-IAA oxidation, which in turn affects the degradation of reactive oxygen species and autophagy in cancer cells.

[0005] Although 3-IAA has made progress in cancer treatment, its potential role in ophthalmology, especially in the prevention and control of myopia and high myopia, is still unknown. As a metabolite derived from the intestinal microbiota, the application of 3-IAA in ophthalmological research may provide new ideas for the prevention and treatment of myopia and high myopia. Future studies can explore the role of 3-IAA in regulating ocular ECM remodeling, slowing scleral thinning, and delaying the progression of high myopia, thereby providing new strategies for the treatment of ophthalmic diseases. Summary of the invention

[0006] The purpose of the present invention is to provide an application of 3-indoleacetic acid in view of the deficiencies in the prior art.

[0007] In a first aspect, the present invention provides the use of 3-indoleacetic acid in products for preventing or alleviating myopia or high myopia.

[0008] As a preferred example, the product is a health product, a medicine or a food.

[0009] As another preferred example, the 3-indoleacetic acid is an intestinal microbiota-related metabolite.

[0010] In a second aspect, the present invention provides an application of a product preparation in a product for preventing or alleviating myopia or high myopia, wherein the product preparation comprises an effective dose of 3-indoleacetic acid and an excipient acceptable to the product.

[0011] As a preferred example, the product is a health product, a medicine or a food.

[0012] As another preferred example, the 3-indoleacetic acid is an intestinal microbiota-related metabolite.

[0013] In a third aspect, the present invention provides the use of 3-indoleacetic acid in a product for regulating increased expression of COL1A1 in the sclera.

[0014] As a preferred example, the product is a health product, a medicine or a food, the 3-indoleacetic acid is a metabolite related to intestinal microbiota, and the disease in which COL1A1 expression in the sclera is reduced is myopia or severe myopia.

[0015] In a fourth aspect, the present invention provides a product preparation for use in a product for regulating increased expression of COL1A1 in the sclera, wherein the product preparation comprises an effective dose of 3-indoleacetic acid and product-acceptable excipients.

[0016] As a preferred example, the product is a health product, a medicine or a food, and the 3-indoleacetic acid is an intestinal microbiota-related metabolite.

[0017] The advantages of the present invention are: 3-IAA is a gut microbiota-related metabolite that is significantly reduced in HM patients. Oral supplementation of 3-IAA in mice leads to increased expression of COL1A1 (type I collagen α1 chain) in the sclera and attenuates myopia progression. 3-IAA increases COL1A1 expression in an SP1-dependent manner, indicating a mechanism by which 3-IAA may contribute to maintaining the structural integrity of the sclera. Regulating the gut microbiota and supplementing 3-IAA are potential therapeutic strategies for preventing or slowing the progression of myopia and HM. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 .The severity of high myopia is associated with gut microbiota dysbiosis.

[0019] (A) Alpha-diversity was evaluated using Chao1 (P = 0.23) and Shannon index (P = 0.84). (B) Beta-diversity was evaluated using principal coordinate analysis (PCoA) based on weighted UniFrac distance. (C) Similarity analysis based on Jaccard distance. (D) Microbial composition at genus level (top 20). (E) Dendrogram of different taxonomic compositions in the healthy control (HC) group and the high myopia (HM) group. The LDA effect size (LEfSe) showed the taxa with significantly different abundances (LDA score > 2). (F) Receiver operating characteristic (ROC) curves and their corresponding areas under the curve (AUC) for differentiating microbial operational taxonomic units (OTUs) in the discovery and validation sets. (G) Heatmap of correlation coefficients between OTUs and two myopia parameters in an independent cohort (n = 73). For the discovery set, n = 45 (HC), n = 52 (HM). For the validation set, n = 23 (HC), n = 26 (HM). *P<0.05, **P<0.01, ns, no significant difference.

[0020] Figure 2 .FMT can delay the progression of high myopia.

[0021] (A) Schematic diagram of the FMT process in mice. (B) Chao1 index (P=0.016) and Shannon index (P=0.016) were used to detect the diversity and abundance of the intestinal microbiota in mice treated with different antibiotic combinations (ABX) and control mice. (C) PCoA plot based on Jaccard distance. (D) Genus-level intestinal microbiota profiles of ABX-treated mice and control mice. (E) Refractive changes of the defocused eye (right eye) and the contralateral eye (left eye). (F) FMT mice receiving healthy controls (FMT HC ), mice receiving FMT from HM patients (FMT HM ), the difference in refractive power between the eyes of ABX-treated mice and control mice. (G) FMT HC 、FMT HM , ABX-treated, and control mice defocused eyes and fellow eyes. (H) FMT HC 、FMT HM, ABX-treated, and control mice. (I) Western blot results show the expression level of COL1A1 protein in the sclera of mice in different groups. β-actin was used as a reference. (J) Immunohistochemistry (IHC) was used to determine the protein level of COL1A1 in the sclera. Scale bar = 25 μm. Data are expressed as mean ± standard error (SEM). Statistical methods: Two-sided Wilcoxon rank sum test (B), one-way ANOVA + Bonferroni correction (F, H) and paired t-test (E, G) were used for evaluation. n = 5 (B, C, D). n = 10 (FMT in E, F, G, H) HC ) and n=11(FMT in E, F, G, H HM ). n=7 (ABX group and control group in E, F, G, and H). *P<0.05, **P<0.01, ***P<0.001.

[0022] Figure 3 .Plasma metabolome profile of HM patients.

[0023] (A) Relative abundance of different types of metabolites in HC and HM patients. (B) Relative abundance of indole in plasma of HC and HM patients (P = 0.0201). (C) Volcano plot showing differential metabolites based on unidimensional statistical analysis. (D) Heat map showing the classification of differential metabolites in plasma of HC and HM patients. (EK) Box plot of significantly differential metabolites between HC and HM patients. (L) Heat map of the strength of correlation between differential plasma metabolites and axial length and refraction. (M) Heat map of the strength of correlation between differential plasma metabolites and significantly altered microbiota. (N) FMT HM and FMT HC The concentration of 3-indoleacetic acid (3-IAA) in mouse plasma. n = 39 (HC group in AM) and n = 49 (HM group in AM). n = 6 (FMT in N HC ) and n=7(FMT in N HM ). Data are presented as median, quartile and minimum / maximum values ​​(EK) or mean ± SEM (C and E). Statistical methods: Unpaired t-test was used for evaluation. *P<0.05, **P<0.01.

[0024] Figure 4 Oral administration of 3-IAA to mice can inhibit the progression of myopia.

[0025] (A) Schematic diagram of the experimental process of mice. (B) Concentration of 3-IAA in peripheral blood 3 hours after oral administration of 3-IAA. (C) Changes in refraction of the defocused eye (right eye) and the fellow eye (left eye). (D) Difference in refractive power between the two eyes. (E) Changes in refractive power between the defocused eye (right eye) and the fellow eye (left eye). (F) Difference in axial length between the two eyes. (G) Western blot results of COL1A1 protein expression level in the sclera. β-actin was used as a reference. (H) IHC detection of COL1A1 protein level in the sclera. Scale bar = 25 μm. Data are expressed as mean ± SEM. Statistical methods: Unpaired t-test (B), paired t-test (C, E) and one-way ANOVA + Bonferroni correction (D, F) were used. n = 5 (control group in B) and n = 6 (3-IAA group in B). n = 9 (FMT in C, D, E, F) HC ) and n = 6 groups (FMT in C, D, E, F HM group and blank group). *P<0.05, **P<0.01, ***P<0.01, ns, no significant difference.

[0026] Figure 5 .3-IAA promotes COL1A1 expression, independent of the AHR pathway (A) Expression levels of COL1A1 mRNA in human embryonic scleral fibroblasts (HFSF) cells. (B, C) Western blot analysis of COL1A1 protein levels in HFSF cells. β-actin was used as a reference. (D, E) Immunofluorescence staining analysis of COL1A1 protein expression in HFSF cells. Scale bar = 20 μm. (F) Western blot analysis of AHR protein levels. β-actin was used as a reference. (G, H) COL1A1 protein levels in HFSF cells transfected with AHR siRNA and treated with 3-IAA and untreated groups. β-actin was used as a reference. Data are expressed as mean ± SEM. Statistical method: unpaired t test (A, C, E, H). n = 4 (control group in A) and n = 5 (3-IAA group in A); n = 3 (C); n = 4 (H). *P<0.05, **P<0.01.

[0027] Figure 6SP1 is involved in 3-IAA-mediated regulation of COL1A1 expression (A) mRNA levels of key genes in COL1A1 biosynthesis. (B, C) Western blot was used to detect the protein levels of COL1A1 and SP1 in HFSF cells. β-actin was used as a reference. (D, E) Immunofluorescence analysis of SP1 protein expression in HFSF cells. Scale bar = 20 μm. (F) HFSF cells were transfected with negative control or SP1 siRNA, and the protein level of SP1 was detected by Western blot. β-actin was used as a reference. (G, H) COL1A1 protein expression level after HFSF cells were transfected with SP1 siRNA and treated with 3-IAA (250 μM). β-actin was used as a reference. Each experiment was repeated three times independently and the results were similar. Data are expressed as mean ± SEM. Statistical method: unpaired t test (A, C, E, H). n = 4 (control group in A) and n = 5 (3-IAA group in A). n=5(C); n=3(H). *P<0.05, **P<0.01.

[0028] Figure 7 SP1 promotes COL1A1 activation after 3-IAA treatment (A) The −2300 / −1600 region of the human COL1A1 gene was analyzed in the Ensembl genome browser. The predicted binding sites of SP1 are underlined. (B) HFSF cells were treated with PBS or 3-IAA (250 μM) for 24 h, and the percentage enrichment of SP1 on the COL1A1 gene was quantified using Cut&tag-qPCR. (C) HFSF cells were transfected with luciferase constructs containing the full-length or truncated promoter elements of human COL1A1, with wild-type SP1 binding sites or mutant binding sites, respectively. After transfection, cells were treated with 3-IAA (250 μM) or PBS for 24 h. Data are presented as mean ± SEM. Statistical analysis: unpaired t-test (B, C). n = 3 (B, C). *P < 0.05, **P < 0.01, ns, not significant. Figure 8 .Gut microbiota regulates the progression of high myopia through the 3-IAA-SP1-COL1A1 pathway.

[0029] In patients with high myopia, dysbiosis of the gut microbiota leads to decreased plasma 3-IAA levels. This reduction in 3-IAA impairs the binding of SP1 to the COL1A1 promoter region in the sclera, inhibits its expression, leads to scleral thinning, and ultimately accelerates the onset of myopia. DETAILED DESCRIPTION

[0030] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.

[0031] Example 1

[0032] I. Materials and Methods

[0033] 1. Subjects

[0034] (1) Research purpose and subject recruitment

[0035] This study aimed to further explore the pathological mechanism of high myopia (HM) and its relationship with the intestinal microbiota by recruiting a homogeneous population with similar geographical location and educational background to reduce external interference factors. HM was defined as binocular axial length (AL) ≥ 26.00 mm, while the healthy control (HC) group was defined as binocular AL between 22.00 mm and 24.50 mm.

[0036] (2) Exclusion criteria and subject screening

[0037] To ensure the accuracy and reliability of the research results, this study set strict exclusion criteria, including but not limited to: history of surgery, infectious or immune-related eye diseases (such as uveitis, cataracts, glaucoma, etc.), history of systemic diseases or taking related drugs, use of antibiotics, glucocorticoids, probiotics / prebiotics in the past three months, and drug abuse or alcoholism. After a careful screening and diagnosis process, this study successfully recruited 97 subjects as the discovery cohort in the discovery cohort, including 52 HM patients (a total of 104 eyes) and 45 HC individuals (a total of 90 eyes). In addition, an independent cohort containing 26 HM, 23 HC, and 24 mild to moderate myopia (24.50≤AL<26.00mm) was established. To further verify the conclusions of the study, the validation set was taken from 26 HM and 23 HC in the independent cohort.

[0038] (3) Data collection and measurement

[0039] For each subject, this study recorded their gender, age, education level, weight, height and other personal information in detail, and calculated the body mass index (BMI) accordingly. Axial length (AL) was used as a key indicator and was accurately measured by experienced technicians using the internationally advanced IOLMaster biometer (model: IOLMaster 700, Carl Zeiss, Germany) to ensure the accuracy and reliability of the data.

[0040] 2. Methods for collecting, storing and processing human samples

[0041] (1) Sample collection

[0042] In order to comprehensively evaluate the biochemical indicators and intestinal flora status of the participants, this study collected peripheral venous blood samples and fecal samples under strict fasting conditions. The specific collection process is as follows:

[0043] Blood sample collection: In the fasting state without food intake, peripheral venous blood samples were collected from participants using standard blood collection equipment. The collected blood samples were first subjected to routine blood tests, including the determination of glycosylated hemoglobin, fasting blood glucose, triglyceride and cholesterol levels. At the same time, according to the national standardized quality control plan, an automatic biochemical analyzer was used to perform detailed analysis of biochemical indicators such as liver and kidney function.

[0044] Fecal sample collection: All participants were required to fast overnight before collecting feces to eliminate the potential impact of food residues on the samples. A dedicated, sterile fecal collection container was used to ensure the purity and integrity of the sample. The collected fresh feces were quickly divided into multiple 5 mL cryovials and stored at -80°C until subsequent molecular biological analysis such as 16S rRNA gene sequencing.

[0045] (2) Sample preservation

[0046] To ensure the stability of the samples and the accuracy of subsequent analysis, all collected samples are processed under strict storage conditions:

[0047] Blood sample processing: 5 mL of peripheral venous blood samples were immediately centrifuged at 2000 rpm for 10 minutes at 4°C to separate plasma and transfer it to a 1.5 mL microtube. All plasma samples were stored in an ultra-low temperature refrigerator at -80°C to prevent the degradation of bioactive substances and ensure the accuracy and reliability of subsequent targeted metabolomics analysis.

[0048] Fecal sample processing: Fecal samples are packaged immediately after collection and quickly frozen at -80°C to maximize the preservation of microbial activity and metabolite information in the samples. This storage condition effectively prevents changes in the microbial community structure and degradation of metabolites, providing high-quality sample resources for subsequent intestinal flora sequencing and functional analysis.

[0049] (3) FMT sample preparation

[0050] In order to conduct a fecal microbiota transplant (FMT) experiment, the fecal sample needs to be specially processed to prepare a fecal suspension. The specific steps include:

[0051] Weighing and dilution: Accurately weigh the appropriate amount of fecal sample and dilute it with PBS to a final concentration of 150 mg / mL to ensure the uniformity and stability of the fecal suspension. After filtering with a 40μM filter, mix it with 20% glycerol and freeze it at -80°C for subsequent FMT experiments. This preparation method ensures the activity and diversity of microorganisms in the fecal suspension, providing a strong guarantee for the success of the FMT experiment.

[0052] 3. Experimental animals and breeding environment

[0053] The male C57BL / 6J mice used in the experiments of the present invention were purchased from Slack Laboratory Animal Co., Ltd. in China to ensure the purity of the strains and consistency of the genetic background of the experimental animals. The mice were raised under specific pathogen-free (SPF) conditions to strictly control the experimental environment and reduce the influence of external interference factors on the experimental results.

[0054] The feeding environment was set up as follows:

[0055] (1) Temperature control: The laboratory maintains a constant temperature of 21°C, which is suitable for the physiological activities and metabolism of mice, ensuring the stability and repeatability of the experimental results.

[0056] (2) Light cycle: A strict 12-hour light / 12-hour dark cycle was adopted, with the light period set from 7 a.m. to 7 p.m. daily to simulate the circadian rhythm changes in nature, which helps maintain the normal physiological rhythm and biological clock stability of mice.

[0057] (3) Humidity regulation: The humidity in the breeding environment is maintained between 55% and 60%. This humidity range helps reduce the growth of dust particles and harmful microorganisms in the air, while keeping the mouse skin and respiratory mucosa moist and maintaining their health.

[0058] (4) Pathogen-free conditions: Through strict cleaning and disinfection measures and environmental monitoring, ensure that the breeding environment is free of specific pathogens, reduce the risk of disease in experimental mice, and ensure the accuracy and reliability of experimental results.

[0059] The present invention relates to a method for constructing a negative lens defocus-induced high myopia (HM) mouse model, which is based on precise ophthalmic operations and strict experimental control, and aims to simulate the pathological process of human high myopia and provide a reliable animal model for subsequent research. The following is a detailed description of the method's steps and optimization:

[0060] (1) Experimental Materials

[0061] A. 4-week-old experimental mice, healthy individuals without eye diseases were selected.

[0062] B.-30D minus lens, used to induce high myopia.

[0063] C. Infrared eccentric photographic ophthalmometer (produced by Steinbeis Translation Center, Germany) was used to measure the refractive power of mice.

[0064] D. Optical coherence tomography (OCT, produced by Towardpi, China), used to measure the axial length of the eye.

[0065] E. Microscopes, ophthalmic surgical instruments and other routine experimental equipment.

[0066] (2) Experimental procedures

[0067] A. Mouse preparation: Select 4-week-old experimental mice and ensure that the mice have no eye diseases or other health conditions that may affect the experimental results.

[0068] B. Induction surgery: A -30D negative lens was fixed on the right eye of the mouse to simulate long-term near visual stimulation. The left eye was used as an untreated control to evaluate the difference between the two eyes. During the surgery, it was necessary to ensure that there were no bubbles or foreign matter between the lens and the cornea to ensure the induction effect.

[0069] C. Postoperative care: After surgery, check the eye condition of the mouse every day to ensure that the lens is firmly fixed and does not fall off or shift. At the same time, pay attention to the eye reaction of the mouse and deal with possible infection or inflammation in time.

[0070] D. Refractive status monitoring: The refraction of mice was measured using an infrared eccentric photographic ophthalmometer on day 1 and day 21. Each measurement was performed three times and the average value was taken to reduce errors and ensure the accuracy and reliability of the data.

[0071] E. Axial length assessment: On day 21, the axial length (AL) of mice was assessed using optical coherence tomography (OCT). OCT technology can non-invasively measure axial length, providing an important basis for analyzing the pathological changes of high myopia.

[0072] (3) Data analysis

[0073] The measured refractive state and axial length data were statistically analyzed to compare the differences between the right eye (induced eye) and the left eye (contralateral eye), as well as the change trends at different time points. Through comparative analysis, the effect of negative lens defocus induction on the formation of high myopia in mice can be evaluated.

[0074] 5. Overview of FMT Experimental Methods

[0075] In order to further study the potential role of intestinal flora in the development of myopia (HM), we designed and performed a fecal microbiota transplantation (FMT) experiment in mice. The specific experimental process and conditions are as follows:

[0076] (1) Intestinal flora depletion stage:

[0077] Mice were first pretreated with broad-spectrum antibiotics (ABX) for one week to deplete their endogenous gut microbiota. The ABX combination included ampicillin (0.25 mg / mL), metronidazole (0.25 mg / mL), neomycin (0.25 mg / mL), and vancomycin (0.25 mg / mL), all dissolved in autoclaved water and supplemented with sucralose (10 mg / mL).

[0078] After antibiotic treatment, bacterial counts in mouse feces were determined by 16S rRNA gene sequencing to confirm successful depletion of the intestinal flora.

[0079] (2) FMT processing stage:

[0080] After the ABX treatment was completed, the mice were given a two-day transition period, and then they were randomly divided into two groups to receive thawed fecal suspension (200 μL) from the HC group or HM patients by gavage, once a day for one week and once every two days for two weeks.

[0081] (3) Experimental monitoring and evaluation:

[0082] During the entire FMT experiment, the mice's general health was monitored, and the refraction and axial length (AL) of the mice were measured regularly.

[0083] 6.3-IAA gavage treatment experimental design

[0084] A. Grouping and treatment: The mice were randomly divided into two groups, namely the experimental group (3-IAA group) and the control group (water group).

[0085] B. Oral gavage operation:

[0086] Starting 7 days before inducing high myopia, the mice in the experimental group were gavaged with 3-IAA solution at a dose of 30 mg / kg / day using a 20G flexible needle to reduce the pain and stress response of the mice.

[0087] The mice in the control group were given the same volume of sterile water by gavage, and the gavage frequency and time point were kept consistent with those of the experimental group.

[0088] Gavages should be performed daily until the end of the experiment (i.e. mice are sacrificed for data collection).

[0089] C. Inducing high myopia: On the 7th day after the start of oral gavage, the two groups of mice were treated to induce high myopia.

[0090] D. Data collection and recording: Regularly record the changes in the refractive power and axial length of mice to evaluate the effect of 3-IAA on the progression of high myopia. At the same time, pay attention to the weight and other physiological indicators of mice to ensure the reliability of the experimental results.

[0091] 7. Collection, processing and storage of mouse samples

[0092] (1) Mouse anesthesia:

[0093] The mice were placed in a dedicated anesthesia device and given a sodium pentobarbital solution (at a dose of 50 mg / kg) by intraperitoneal injection.

[0094] Wait until the mouse is fully anesthetized before proceeding.

[0095] (2) Eyeball and blood collection:

[0096] Use sterile surgical instruments to quickly remove the mouse eyeball, and be careful to avoid damaging surrounding tissues during the operation.

[0097] At the same time, blood samples were collected from the heart or jugular vein of mice for subsequent plasma metabolite analysis.

[0098] (3) Sample processing:

[0099] Blood samples were centrifuged at 2000 rpm for 10 min at 4 °C to separate plasma for subsequent metabolomics analysis.

[0100] After the eyeballs were collected, the sclera tissue was immediately and carefully peeled off under sterile conditions for molecular biology or histological studies.

[0101] (4) Sample preservation:

[0102] The separated plasma and scleral tissue were quickly transferred into pre-prepared cryovials.

[0103] All samples were frozen in an ultra-low temperature freezer at -80°C to prevent sample degradation and ensure the accuracy and reliability of subsequent experiments.

[0104] 8.16S rRNA gene sequencing and processing

[0105] (1) DNA extraction and quality control: The OMEGA Soil DNA Kit (M5635-02) was used to efficiently extract bacterial genomic DNA from stool samples. The DNA concentration was assessed using a NanoDrop NC2000 spectrophotometer, and the integrity and purity of the DNA were verified by agarose gel electrophoresis.

[0106] (2) PCR amplification and purification: The V3-V4 region of the bacterial 16S rRNA gene was amplified using specific paired primers. The product was purified using Vazyme VAHTSTM DNA cleaning beads and then accurately quantified using the Quant-iT PicoGreen dsDNA detection kit.

[0107] (3) Sequencing preparation and high-throughput sequencing: Construction of sequencing library. High-throughput sequencing was performed using the Illumina NovaSeq platform to generate raw data, which were then processed to conduct in-depth analysis of the structure and evolutionary relationships of the microbial community. Data analysis was performed using QIIME2 and R software packages (v3.2.0).

[0108] 9.Western blotting, immunohistochemical staining, immunofluorescence staining

[0109] All experimental operations followed conventional standardized experimental steps.

[0110] 10. Target Plasma Analysis

[0111] Standards provided by suppliers such as Sigma-Aldrich, Steraloids Inc. and TRC Chemicals were used as references for targeted metabolites. Sample preparation: 20 μL of plasma was thoroughly vortexed with 120 μL of ice methanol for 5 minutes, the supernatant was separated by centrifugation, 30 μL was mixed with 20 μL of freshly prepared derivatization reagent, incubated at 30°C for 60 minutes, 330 μL of ice methanol solution (50% concentration) was added to the sample, cooled at -20°C for 20 minutes, and then centrifuged at 4000g for 30 minutes at 4°C to further purify the sample. 135 μL of supernatant was transferred to a new container and 10 μL of internal standard was added for mixing. The treated plasma samples were subjected to UPLC-MS / MS analysis. The raw data were processed by QuanMET software (v2.0, Metabo-Profile, Shanghai). Finally, 193 metabolites in plasma were successfully detected and quantified, providing important data support for subsequent biological research, disease diagnosis and drug development.

[0112] 11.Measurement of 3-indoleacetic acid (3-IAA) content in organisms

[0113] Mice were treated with 3-IAA or water as a control via intragastric administration for one week. Three hours after the last dose, enucleation was performed and scleral tissue was collected. Scleral tissue from five mice was pooled into one sample for each experiment, and each experiment contained three such pooled samples to ensure data reliability and repeatability. Scleral samples and plasma samples were analyzed by LC-MS / MS to detect 3-IAA content.

[0114] 12. Cell Culture and Treatment

[0115] HFSFs cells were derived from the Cell Resource Center, Chinese Academy of Medical Sciences and Peking Union Medical College (IBMS, CAMS / PUMC, Beijing, China) and were cultured using standard cell culture techniques.

[0116] Specifically, HFSFs cells were cultured in DMEM medium containing 10% fetal bovine serum (FBS) to ensure sufficient nutrients for their growth. The culture conditions were maintained at a constant temperature of 37°C, with a normal humidity incubator and 5% CO 2 concentration to simulate the microenvironment of cell growth in vivo.

[0117] 3-IAA was completely dissolved in 1N NaOH solution, and then the pH of the solution was adjusted to a physiologically suitable 7.4 by adding 25% (v / v) HCl. This step ensures the effectiveness and stability of 3-IAA in subsequent experiments. Subsequently, different concentrations of 3-IAA solutions were applied to HFSFs cells for 24 hours or 48 hours of pre-incubation. Prior to this, the cells were starved of fetal bovine serum for 6 hours to eliminate possible interfering factors in the serum.

[0118] 13. RNA extraction and real-time fluorescence quantitative PCR analysis

[0119] (1) RNA extraction: Total RNA was extracted using the EZ-press RNA Purification Kit (B0004D, EZ Bioscience, China) in strict accordance with the manufacturer's instructions. This kit ensures the integrity and purity of RNA samples with its high efficiency, high purity, and easy operation, laying a solid foundation for subsequent experiments.

[0120] (2) RNA quantification: The extracted RNA was accurately quantified using a Nanodrop spectrophotometer (ThermoFisher Scientific, USA) to ensure that the RNA concentration was within an appropriate range to meet the requirements of the subsequent reverse transcription reaction.

[0121] (3) Reverse transcription to cDNA: RNA was reverse transcribed into cDNA using HiFiScript gDNA Removal RT MasterMix kit (CW2020, CWBIO, China). This kit integrates the genomic DNA removal function, which effectively avoids the interference of genomic DNA on qPCR results and improves the accuracy of experimental results.

[0122] (4) Real-time fluorescence quantitative PCR (qPCR): Using cDNA as a template, qPCR analysis was performed on the BioRad real-time PCR system (USA) using MagicSYBR Mixture (CW3008, CWBIO, China). By precisely controlling the reaction conditions and combining specific primers (primer sequences are detailed in Table 1), sensitive and rapid detection of target gene expression levels was achieved.

[0123] Table 1

[0124]

[0125]

[0126]

[0127] 16. Overview of CUT&Tag Assay Method

[0128] (1) Cell treatment: First, human fetal scleral fibroblasts (HFSF cells) were evenly plated in a six-well plate and divided into two groups. One group was treated with phosphate buffered saline (PBS) as a control group, and the other group was treated with 500 μM 3-IAA for 24 hours to simulate or activate specific cell signaling pathways.

[0129] (2) CUT&Tag reaction: CUT&Tag experiments were performed using the NovoNGS ChiTag Transposon Kit (N259-YH01-01A, Novoprotein). The treated cells were collected and subjected to a series of chemical and enzymatic reactions according to the detailed guidelines provided by the manufacturer. At the same time, a negative control group using rabbit IgG as the antibody was set up to exclude nonspecific binding.

[0130] (3) DNA purification and PCR amplification: After the CUT&Tag process, the obtained DNA fragments were purified. Subsequently, PCR amplification was performed using primers designed for the specific region of the human COL1A1 gene promoter (-2169 bp to -2164 bp). The primer sequences are as follows: forward primer 5'CCTTGGAGGTTTCAACTCTT3' (SEQ ID NO: 29), reverse primer 5'GTTTCCCATCCAGGCTTT3' (SEQ ID NO: 30).

[0131] 17. Luciferase Assay

[0132] (1) Cell preparation: Human fetal scleral fibroblasts (HFSFs) were seeded in a 96-well plate to ensure that the cell density was appropriate to provide a good environment for subsequent transfection.

[0133] (2) Transfection operation: Use the highly efficient transfection reagent Lipofectamine 3000 (Thermo Fisher Scientific, USA).

[0134] (3) Drug treatment: After transfection, cells were allowed to recover for 24 hours and then exposed to 3-IAA or its vector control and cultured for another 24 hours. This step was designed to explore the effect of 3-IAA on the activity of the target promoter.

[0135] (4) Enzyme activity detection: The cells were harvested and lysed using the Dual-Luciferase Reporter Assay System (Yeasen, China), and the activities of firefly luciferase and Renilla luciferase were measured respectively. By comparing the luciferase activity ratio between the treatment group and the control group, the effect of 3-IAA on col1a1 promoter activity can be accurately quantified.

[0136] 18. Mendelian randomization (MR) analysis

[0137] (1) Data source:

[0138] Exposure data: Large-scale GWAS data on gut microbiota obtained from the GWAS Catalog (GCST90027446-GCST90027857), involving a total of 7738 samples.

[0139] Results: Summary statistics of the myopia GWAS from the FinnGen study (finn-b-H7_MYOPIA), including 1640 myopic patients and 210,931 controls.

[0140] (2) Genetic instrumental variable screening:

[0141] Strict criteria were applied to screen genetic instrumental variables, including GWAS P value less than 1×10^-5, linkage disequilibrium (LD) r 2 The LD distance was less than 0.001, the F statistic was greater than 10,000 kb, and the validity and independence of the selected variables were ensured.

[0142] The Steiger directional test was used to verify the causal direction of each instrumental variable.

[0143] All SNPs used for analysis were checked by LDlink platform.

[0144] (3) MR analysis method:

[0145] Four MR analysis methods were implemented using the "TwoSampleMR" R package: inverse variance weighting (IVW), MR-Egger regression, weighted median method, and weighted mode method. Among them, the IVW method was used as the main method to estimate the association between gut microbiota characteristics and myopia risk.

[0146] Cochrane's Q method and MR-Egger intercept were used to test heterogeneity and potential horizontal pleiotropy in MR analysis, respectively.

[0147] 19. Statistical analysis and reproducibility

[0148] 20. To ensure the accuracy and reliability of data analysis, we strictly followed statistical principles and used a variety of statistical methods to adapt to the characteristics of different data types. All statistical analysis was completed using GraphPad Prism v8 and R v3.3.2 software to ensure the professionalism of the analysis process and the accuracy of the results.

[0149] 21. For data sets that conform to normal distribution, we use paired two-tailed t-test to evaluate whether the difference between the eyes of the same animal is statistically significant. When it is necessary to compare the differences between the eyes of different groups, we flexibly choose unpaired t-test, one-way analysis of variance (ANOVA) or two-way ANOVA according to the needs of the experimental design, supplemented by Bonferroni correction, to accurately identify significant differences between groups.

[0150] 22. For variables that do not meet the normal distribution assumption, we used the Wilcoxon rank sum test, a non-parametric method that can effectively handle skewed distribution data and ensure the robustness of statistical inference.

[0151] 23. When exploring the correlation between variables, we calculated the Spearman correlation coefficient r value and corrected the p value in multiple comparisons using the Benjamini-Hochberg method to more accurately assess the strength of the correlation between variables.

[0152] 24. In addition, for the comparison of categorical variables, we used the chi-square test and Fisher's exact test, which can effectively assess whether the differences between different categories are statistically significant.

[0153] In the present invention, the significance level of all statistical tests is set to α=0.05, that is, when the p value is less than 0.05, we consider the difference or correlation to be statistically significant. This strict significance standard ensures the reliability and repeatability of the experimental results, and provides solid data support for the scientific nature and application value of the present invention.

[0154] 2. Results

[0155] 1. Summary of baseline characteristics of the study population

[0156] In this study, we compared the clinical characteristics of the healthy control group (HC) and the high myopia group (HM) in detail, and these data are summarized in Table 2 below. The discovery group and the validation group were well matched in terms of age, sex, body mass index (BMI), and education level. In addition, no significant differences were observed in fasting blood glucose or biochemical measurements, including liver and kidney function. Specifically, significant differences were observed between the HM and HC groups in terms of mean AL, refractive error, anterior chamber depth (ACD), and lens thickness (LT).

[0157]

[0158] 2. The severity of HM is associated with intestinal microbiota dysbiosis

[0159] This study conducted an in-depth analysis of the participants' stool samples using 16S rRNA gene sequencing ( Figure 1 ).

[0160] (1) Microbial diversity analysis:

[0161] Alpha diversity: Chao1 and Shannon index analysis showed that there was no significant difference in the richness and diversity of intestinal microorganisms between the high myopia group (HM) and the healthy control group (HC) ( Figure 1 a), indicating that the two groups were similar in overall microbial richness and diversity.

[0162] Beta diversity differences suggested significant differences in microbial community structure between the two groups (Adonis: R2 = 0.015, p = 0.001), indicating that the microbial composition of the HM group at the operational taxonomic unit (OTU) level was unique ( Figure 1 b).

[0163] (2) Microbial composition analysis:

[0164] Through LefSe analysis, the iconic bacteria associated with HM were identified. The results showed that in the HM group, Akkermansia, Fusobacteriaceae, Parvimonas and other bacteria decreased, while Gemmatimonadetes, Butyricicoccus and other bacteria increased ( Figure 1 e). In particular, Akkermansia, a probiotic with multiple disease associations, had the highest LDA score (>4) and was significantly reduced in both univariate and multivariate analyses.

[0165] The discriminative ability of intestinal bacteria in distinguishing HM was verified by the area under the curve (AUC) values, which were 0.837 and 0.890 in the discovery and validation sets, respectively ( Figure 1 f), indicating the reliability of these bacteria as biomarkers.

[0166] (3)Causal analysis:

[0167] MR results showed that a total of 14 bacteria had a significant causal association with myopia. In particular, g_Akkermansia was identified as a protective factor for myopia (OR = 0.797, 95% CI = 0.637–0.997, p = 0.047). MR-Egger did not find a potential impact of horizontal pleiotropy on the results (p>0.05).

[0168] In an independent cohort, we further analyzed the correlation between the altered bacterial genera abundance and myopia severity indicators (axial length AL and diopter) and found that Akkermansia was negatively correlated with axial length ( Figure 1 g).

[0169] 3. A healthy gut microbiota is necessary to maintain COL1A1 expression in the sclera to delay HM To clarify the causal relationship between changes in the gut microbiota and myopia progression,

[0170] In this study, fecal microbiota transplantation (FMT) experiments were performed in which fecal samples from healthy controls (HC) and high myopia (HM) were transplanted into antibiotic pretreated (ABX) C57BL / 6J wild-type mice, and then a minus lens-induced myopia model was induced in the mice.

[0171] Evaluation of fecal microbiota transplantation effect: Fecal suspensions from HC and HM populations were transplanted to ABX-treated mice (labeled as FMTHC group and FMTHM group, respectively). Although Alpha diversity analysis did not show significant differences between the two groups, PCoA analysis showed that the intestinal microbiota structure of FMTHC and FMTHM mice was significantly separated, and the relative abundance of Akkermansia bacteria (a genus that was significantly reduced in the HM group) in the FMTHM group was lower than that in the FMTHC group, indicating that FMT successfully achieved the transplantation and colonization of intestinal microbiota.

[0172] Myopia progression assessment: Compared with the FMTHM and ABX groups, the myopia progression of mice in the FMTHC group was significantly slowed down, as shown by a 34.0% reduction in refractive error (from -7.38D to -4.87D) and a 51.5% reduction in axial lengthening (from 85.79μm to 41.63μm). This result strongly suggests that restoring a healthy intestinal microbiota can effectively alleviate myopia progression.

[0173] Gene expression analysis: COL1A1, as a major component of the scleral extracellular matrix (ECM), is expressed less during the development of myopia. FMTHC treatment significantly inhibited the reduction of scleral COL1A1 expression caused by HM, further supporting the key role of the gut microbiota in regulating the development of myopia (see Figure 2 ).

[0174] 4. Intestinal microbiota dysbiosis leads to decreased plasma 3-IAA levels

[0175] Inspired by the host-microbe metabolic axis theory, we performed targeted quantitative metabolomics analysis on plasma samples from HC and HM patients and identified a total of 193 metabolites.

[0176] Key findings:

[0177] A. It was found that the levels of indole metabolites in the plasma of the HM group were significantly decreased.

[0178] B. Changes in specific metabolites: The decrease in 3-IAA was most significant in the HM group. This finding suggests that gut microbiota dysbiosis may directly affect the level of 3-IAA in plasma.

[0179] C. Correlation analysis: 3-IAA in plasma was negatively correlated with axial length (AL), while 3-IAA was positively correlated with the degree of refractive error. In addition, the abundance of Akkermansia bacteria was positively correlated with 3-IAA levels in both HM and HC groups, suggesting that Akkermansia may play an important role in regulating 3-IAA levels. Functional verification: Through FMT, the intestinal flora of HC and HM subjects were transplanted into myopia model mice. The results showed that the intestinal flora of HC and HM subjects were transplanted into myopia model mice. HC The plasma 3-IAA concentration in the group was significantly higher than that in the mice receiving HM microbiota transplantation (FMT HM This finding further confirms the superiority of healthy gut microbiota in producing 3-IAA and highlights the potential role of 3-IAA in myopia progression mediated by the gut-eye axis (see Figure 3 ).

[0180] 5. Daily supplementation of 3-IAA can alleviate the progression of HM by promoting the expression of COL1A1 in the sclera

[0181] To further investigate the potential effects of 3-IAA in the development of myopia, mice were supplemented with 3-IAA by daily intragastric instillation for four weeks, starting 7 days before myopia induction ( Figure 4a). During normal refractive development, 3-IAA treatment had no significant effect on the refraction and body weight of mice. However, the key finding was that 3-IAA significantly increased the concentration of 3-IAA in plasma and sclera, from 189.1 fmol / μL to 1123 fmol / μL, respectively ( Figure 4 b) and increased from 0.0073ng / g to 0.0145ng / g.

[0182] Further analysis showed that the defocused eyes of mice that only received negative lens-induced myopia or mice that simultaneously received high myopia modeling and 3-IAA supplementation had significant myopic refractive shift and axial length (AL) elongation, which was more significant than that of the untreated group (blank group). Figure 4 c,e). It is noteworthy that the myopic refractive error of mice in the 3-IAA group was reduced by 51.9% (–3.81D) and the axial lengthening was reduced by 35.9% (53.30μm in the control group vs 34.17μm in the 3-IAA group) compared with the control group (–7.92D). Figure 4 Importantly, 3-IAA treatment significantly alleviated the myopia-induced decrease in COL1A1 levels in the sclera of mice ( Figure 4 g, h).

[0183] 6.3-IAA promotes COL1A1 expression in vitro, independent of the aryl hydrocarbon receptor (AHR) pathway

[0184] To explore the effect of 3-IAA on COL1A1 expression, this experiment used HFSF cells as a model and applied 250 μM concentration of 3-IAA treatment. The results showed that 3-IAA treatment significantly promoted the expression of COL1A1 in mRNA ( Figure 5 a) and protein levels ( Figure 5 be) expression.

[0185] Given that 3-IAA is known to be an endogenous ligand of the aryl hydrocarbon receptor (AHR), we further investigated whether 3-IAA promotes the expression of COL1A1 through the AHR pathway. By detecting the mRNA expression level of CYP1A1, a signature target gene of AHR, we found that 3-IAA significantly increased the expression of CYP1A1, confirming the activation of the AHR signaling pathway in HFSFs. However, when AHR was knocked down in HFSFs using siRNA technology ( Figure 5 f), the stimulatory effect of 3-IAA on COL1A1 expression was not abolished ( Figure 5 g, h).

[0186] 7.3-IAA transcriptionally activates COL1A1 expression by enhancing the enrichment of SP1 in the COL1A1 promoter region

[0187] To explore the molecular mechanism of 3-IAA regulating COL1A1 expression, we first detected the expression of key transcription factors involved in COL1A1 regulation. The results showed that 3-IAA was expressed in mRNA ( Figure 6 a) and protein ( Figure 6 be) levels, SP1 is a key transcription factor involved in collagen regulation and myopia development. In contrast, 3-IAA treatment had no significant effect on the mRNA expression of other regulatory factors such as SP3, SMADs, c-JUN, etc. in HFSF ( Figure 6 a). Furthermore, after inhibiting SP1 by siRNA, the stimulatory effect of 3-IAA on COL1A1 expression was completely abolished ( Figure 6 h), indicating that SP1 plays a key role in 3-IAA regulation of COL1A1 expression.

[0188] In animal experiments, we also observed that FMT HC The expression level of SP1 protein in the sclera of mice in the 3-IAA treatment group and the 3-IAA treatment group was significantly increased, and this change was consistent with the expression trend of COL1A1.

[0189] To clarify how 3-IAA regulates COL1A1 expression through SP1, we used the JASPAR database to analyze the nucleotide sequence of 2500 bp upstream of the COL1A1 coding sequence and found two classic SP1 binding sites (GGGCGG), located at -2169 bp to -2164 bp and -1614 bp to -1609 bp, respectively, with the highest score ( Figure 7 a). Subsequently, the binding of SP1 to the COL1A1 promoter region was detected in HFSF by CUT&Tag assay. The results showed that 3-IAA treatment significantly enhanced the enrichment of SP1 in the COL1A1 promoter region ( Figure 7 b).

[0190] To further verify the specificity of the binding site, we constructed a firefly luciferase reporter gene system driven by the human COL1A1 gene promoter and found that 3-IAA significantly upregulated the COL1A1 promoter activity. When the predicted binding site was truncated (located at -2000bp), 3-IAA could only promote the activity of the wild-type COL1A1 promoter, but had no effect on the truncated type ( Figure 7 c).

[0191] III. Discussion

[0192] This study investigated the relationship between high myopia (HM) and changes in intestinal flora, and provided a new perspective on the pathogenesis of myopia and HM. The main findings include:

[0193] 1. Alterations in intestinal flora: Significant differences in the composition of intestinal flora were observed between HM patients and healthy controls (HC). Notably, HM patients showed a decrease in multiple bacteria such as Akkermansia, Fusobacteriaceae, and Parvimonas, while an increase in bacteria such as Gemmatimonadetes and Butyricicoccus.

[0194] 2. Effect of Akkermansia: Akkermansia is a beneficial microorganism that was the most significantly reduced species in HM subjects and was strongly negatively correlated with the severity of HM. This suggests that Akkermansia has a protective effect on myopia and HM progression.

[0195] 3. Fecal microbiota transplantation: Fecal microbiota transplantation from healthy control subjects into HM model mice can significantly improve the progression of myopia and HM, supporting the view that changes in the intestinal microbiota can affect the development of myopia and HM.

[0196] 4.3-Indoleacetic acid (3-IAA): 3-IAA is a gut microbiota-associated metabolite that is significantly altered in HM patients. Oral supplementation of 3-IAA in mice resulted in increased expression of COL1A1 (type I collagen α1 chain) in the sclera and alleviated myopia and HM progression.

[0197] 5. Mechanism of action: 3-IAA increases COL1A1 expression in an SP1-dependent manner, suggesting that 3-IAA may contribute to the mechanism by which sclera structural integrity is maintained.

[0198] 6. Potential therapeutic significance: This study suggests that regulating intestinal microbiota and supplementing 3-IAA may be potential therapeutic strategies to prevent or slow the progression of myopia and HM.

[0199] 7. Lifestyle factors: Abnormal light exposure and circadian rhythm disruption are known risk factors for myopia and can also alter the composition of the gut microbiota, providing a possible link between lifestyle factors and the development of myopia and HM.

Claims

1. 3-Indoleacetic acid is used in products for preventing or slowing down myopia and high myopia.

2. The use according to claim 1, characterized in that: The product is a health product, a medicine or a food.

3. The use according to claim 1 or 2, characterized in that: The 3-indoleacetic acid is an intestinal microbiota-related metabolite.

4. Use of a product preparation in a product for preventing or alleviating myopia or high myopia, characterized in that: The product preparation comprises an effective dose of 3-indoleacetic acid and adjuvants acceptable to the product.

5. The use according to claim 4, characterized in that: The product is a health product, a medicine or a food.

6. The use according to claim 4 or 5, characterized in that: The 3-indoleacetic acid is an intestinal microbiota-related metabolite. 7.3-Indoleacetic acid for use in products that modulate increased COL1A1 expression in the sclera.

8. The use according to claim 7, characterized in that: The product is a health product, a medicine or a food, the 3-indoleacetic acid is a metabolite related to intestinal microbiota, and the disease in which COL1A1 expression in the sclera is reduced is myopia or high myopia.

9. Use of a product preparation in a product for regulating increased expression of COL1A1 in the sclera, characterized in that: The product preparation comprises an effective dose of 3-indoleacetic acid and adjuvants acceptable to the product.

10. The use according to claim 9, characterized in that: The product is a health product, a medicine or a food, and the 3-indoleacetic acid is a metabolite related to intestinal microflora.

Citation Information

Cited By

  • Application of indoleacetic acid in preparation of medicine or food for treating optic nerve injury

    CN120617248A

  • Application of bacteroides fragilis in preparation of medicine or food for treating optic nerve injury

    CN121221648A

  • Application of Bacteroides fragilis in the preparation of drugs for treating optic nerve damage

    CN121221648B